Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vanda Pharmaceuticals reports mixed Q4 results amid legal challenges and opportunities

Vanda Pharmaceuticals faces financial challenges with declining revenues and HETLIOZ sales, offset by increased cash reserves and positive clinical trial outcomes.
Legal battles and uncertainties add complexity to the company's financial outlook, requiring strategic planning and risk management.
Despite hurdles, opportunities for growth exist through new drug applications, market expansion, and potential partnerships to drive future success.

Vanda Pharmaceuticals reports resilient Q1 performance amidst generic challenges

Vanda Pharmaceuticals delivered a strong performance in Q1 2023, navigating challenges from generic competition while focusing on growth opportunities.
The company's financial results and strategic initiatives position it well for future expansion and innovation in the pharmaceutical industry.
Despite uncertainties surrounding litigation and generic competition, Vanda remains resilient and committed to driving long-term value for stakeholders.

Vanda Pharmaceuticals navigates revenue decline, eyes regulatory approvals for growth

Vanda Pharmaceuticals faced revenue challenges due to generic competition impacting HETLIOZ sales, leading to a revenue decline.
Despite legal uncertainties and revenue setbacks, the company showcased strength in pipeline progress and operational cost management.
Management's confidence in regulatory outcomes and strategic flexibility positions Vanda for potential growth opportunities.

Vanda Pharmaceuticals reports revenue decline but maintains positive net income

Vanda Pharmaceuticals faces revenue challenges with declining total revenues and net product sales in 2023.
Despite this, the company maintains positive net income and focuses on upcoming FDA decisions for growth.
Strong leadership, operational efficiency, and a diversified product portfolio are key strengths for Vanda.
Exploring growth opportunities through FDA decisions, market expansion, and strategic initiatives is crucial for future success.

Vanda Pharmaceuticals reports revenue decline, pursues new treatments amid challenges

Vanda Pharmaceuticals faced revenue declines and net losses in Q4 2023, driven by challenges in product sales and market conditions.
Despite these setbacks, the company is strategically expanding its product portfolio and pursuing new treatments to drive future growth.
Navigating legal battles, generic competition, and market uncertainties will be key focus areas for Vanda in the coming year.

Vanda Pharmaceuticals navigates revenue challenges, eyes growth through strategic initiatives

Vanda Pharmaceuticals faced revenue challenges due to generic competition but remains focused on driving growth through commercial strategies.
The company's psychiatry portfolio expansion and ongoing clinical programs position it well for future market opportunities.
Addressing shareholder activism and evaluating takeover proposals while maintaining operational focus are key challenges ahead.
Engaging with the FDA for product approvals and planning strategic marketing initiatives offer avenues for revenue growth.

Vanda Pharmaceuticals reports revenue growth and strategic expansion plans

Vanda Pharmaceuticals is navigating a mixed financial performance with revenue growth but a net loss in Q2 2024. The company's focus on expanding its commercial organization and advancing clinical development indicates a strategic approach to drive future growth amidst challenges from generic competition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WASHINGTON , May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022. The following scientific posters will be presented: June 7, 2022 Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsPoster Session Presentation Time: 5:15 PM – 7:15 PM ET Title: "Enrichment of RAI1 genetic aberrations associated with sleep disturbances in SMS, in Autism Spectrum Disorder"  Poster Number: 007 Title: "A 10-week observational research study in individuals with delayed sleep-wake phase disorder (DSWPD) symptoms"Poster Number: 028 Title: "A novel missense variant in Melanopsin associates with delayed sleep phenotype: whole-genome sequencing study"  Poster Number: 285 For more information on SLEEP 2022, please refer to https://www.sleepmeeting.org/.

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

WASHINGTON , May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022. The following will be presented: May 21, 2022 Presentation Title: "THE ROLE OF M1 TO M2 MACROPHAGE POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS PERSPECTIVE"Abstract Number: 3752409Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsSession Type: Plenary SessionSession Title: Late-Breaking Basic Science Abstract PlenarySession Time: 2:00 PM to 3:30 PM PDT Presentation Time: 2:15 PM to 2:30 PM PDT May 23, 2022 Presentation Title: "ENRICHMENT OF PATIENTS WITH EHLERS DANLOS SYNDROME IN IDIOPATHIC GASTROPARESIS – A GENE SET ENRICHMENT ANALYSIS"Abstract Number: 3696881Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsSession Type: Poster SessionSession Title: Cell Biology, Biochemistry and Integrative PhysiologySession Time: 12:30 PM to 1:30 PM PDT For more information on DDW 2022, please refer to https://ddw.org/.

Vanda Pharmaceuticals Announces Presentations at DDW 2022

I am quite impressed with Vanda Pharmaceuticals' investing thesis. Though it cooled off recently, Vanda is still positing significant revenues that I expect would leap to a higher level either next year or beyond.

Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran – Senior Vice President & Chief Financial Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by.

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael H. Polymeropoulos on Q1 2022 Results - Earnings Call Transcript

WASHINGTON , May 5, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022. "We are excited with our progress in improving patient access for HETLIOZ®, especially for Medicaid beneficiaries with Non-24 and SMS diagnoses," said Mihael H.

Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results

WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022. A corporate presentation is scheduled for 4:00 p.m.

Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference

Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Thursday, May 5, 2022, during which management will discuss the first quarter 2022 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline

Amid the biotech bear market, many fundamentally sound companies are trading at a fraction of their intrinsic value.

Vanda: A Dual Growth And Value Player

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results - Earnings Call Transcript

WASHINGTON, Feb. 23, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2021. "We are proud of the progress we have made this past year with our existing products and in bringing HETLIOZ® to patients with Smith-Magenis Syndrome, leading to a strong financial performance, even in the face of extraordinary challenges," said Mihael H.

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, February 23, 2022, during which management will discuss the fourth quarter and full year 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Vanda Pharmaceuticals Inc  VNDA shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are Vanda Pharma Shares Plunging Today?

WASHINGTON, Feb. 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its prespecified primary endpoint which was the difference between drug and placebo on the change of the severity of nausea from baseline at week 12 of treatment.

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis

WASHINGTON, Jan. 14, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda's patent litigation against MSN regarding MSN's Abbreviated New Drug Application seeking approval of its generic version of Vanda's HETLIOZ® (tasimelteon). Under the License Agreement, Vanda granted MSN and Impax a non-exclusive license to manufacture and commercialize MSN's version of HETLIOZ® in the U.S. effective March 13, 2035, unless prior to that date Vanda obtains pediatric exclusivity for HETLIOZ®, in which case, the license will be effective July 27, 2035.

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

Amid the 2021 Biotech Bear market, there are many fundamentally strong companies trading at a deep discount to their true worth. As a growth/value play, Vanda Pharmaceuticals is a promising investment with substantial upsides.

Vanda: A Prudent Business With Upsides

WASHINGTON, Nov. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in November 2021: The Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021. A corporate presentation is scheduled for 10:00 a.m.

Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2021 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of -30.00% and -4.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Misses Q3 Earnings and Revenue Estimates

Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Vanda Pharmaceuticals: Q3 Earnings Insights

WASHINGTON, Nov. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2021. "Vanda is approaching another pivotal moment in its 18-year history with the upcoming completion of the Phase III study of tradipitant in gastroparesis and anticipated results by the end of this year.

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

Vanda Pharmaceuticals Earnings Preview

WASHINGTON, Oct. 27, 2021 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 3, 2021, during which management will discuss the third quarter 2021 financial results and other corporate activities.

News for Vanda Pharmaceuticals Stock (VNDA)